(MedPage Today) — The investigational orexin receptor 2 (OX2R) agonist oveporexton improved cognitive symptoms of narcolepsy type 1 (NT1) in secondary analysis of a phase II trial.
The oral agent improved attention, memory, and executive function…
Source link : https://www.medpagetoday.com/neurology/sleepdisorders/118910
Author :
Publish date : 2025-12-09 16:57:00
Copyright for syndicated content belongs to the linked Source.
